The multinational of Grifols blood products has presented this Saturday the results of a clinical trial that shows a slowdown of 61% in the progression of Alzheimer's in patients of moderate stage, in a new step towards a possible way of treatment against this neurodegenerative disease in some patients. The trial, called Ambar (Alzheimer's Management by Albumin Replacement), had the participation of 496 patients from 41 hospitals in the United States and Spain, and has consisted in the combination of the periodic extraction of plasma and its replacement by an albumin solution. , a plasma protein.
This treatment is based on the hypothesis that the majority of beta-amyloid, one of the proteins that accumulates in the brain of people with Alzheimer's, circulates in plasma bound to albumin. The extraction of this plasma could displace the beta-amyloid of the brain into the plasma, limiting the impact of this disease on the cognitive functions of the patient.
According to Grifols, in the population of patients with moderate-stage Alzheimer's, the results have shown, with statistical significance, a slowdown of 61% in the progression of the disease, improving both the cognitive capacity and the development of daily activities. In the group of patients in mild stage the results have not reached a statistical significance in the slowing down in the progress of the disease.
Ambar is an international clinical trial, multicenter and double-blind -the patients do not know if they have received treatment or placebo- in which about half a thousand Alzheimer's patients have participated in a mild and moderate state between 55 and 85 years. The development of the new drug thus faces its final stage, in which it must ratify the results obtained to date in much larger samples of patients and, subsequently, obtain the approval of the health authorities for its future release to the market.
The president of Grifols, Víctor Grifols, argues that these results "open a new pathway in the treatment of Alzheimer's disease" and remarked that his company "will continue to explore the potential of plasma proteins and plasma exchange in subsequent studies."